[Seite 85↓]


[1] Kirwan, J. R. (1995): The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group, N Engl J Med, (vol. 333), No. 3, pp.142-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7791815

[2] Weusten, B. L.; Jacobs, J. W. and Bijlsma, J. W. (1993): Corticosteroid pulse therapy in active rheumatoid arthritis, Semin Arthritis Rheum, (vol. 23), No. 3, pp.183-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8122121

[3] Youssef, P. P.; Cormack, J.; Evill, C. A.; Peter, D. T.; Roberts-Thomson, P. J.; Ahern, M. J. and Smith, M. D. (1996): Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis, and the effects of methylprednisolone, Arthritis Rheum, (vol. 39), No. 2, pp.216-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8849371

[4] Youssef, P. P.; Haynes, D. R.; Triantafillou, S.; Parker, A.; Gamble, J. R.; Roberts-Thomson, P. J.; Ahern, M. J. and Smith, M. D. (1997): Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis, Arthritis Rheum, (vol. 40), No. 8, pp.1400-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9259419

[5] Hall, E. D. (1992): The neuroprotective pharmacology of methylprednisolone, J Neurosurg, (vol. 76), No. 1, pp.13-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1727150

[6] Bracken, M. B.; Shepard, M. J.; Collins, W. F., Jr.; Holford, T. R.; Baskin, D. S.; Eisenberg, H. M.; Flamm, E.; Leo-Summers, L.; Maroon, J. C.; Marshall, L. F. and et al. (1992): Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study, J Neurosurg, (vol. 76), No. 1, pp.23-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1727165

[7] Hatz, Hans J. ( 1998, ), Glucocorticoide - Immunologische Grundlagen, Pharmakologie und Therapierichtlinien (Vol., p.^pp. 169-264, 552-554, Wissenschaftliche Verlagsgesellschaft Stuttgart, Stuttgart.

[8] Hatz, H. J. and Helmke, K. (1992): Polymyalgia rheumatica und Riesenzellarteriitis; Diagnostik und Nebenwirkungsprofil bei niedrig-dosierter Glukokortikoidlangzeittherapie, Z Rheumatol, (vol. 51), No. 5, pp.213-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1476006

[9] Helmke, K, Glombik Th, Kuckein D, Stein A (1998): Steroid-Osteopenie und Osteoporose unter Methylprednisolon-oder Fluocortolon-Therapie, Aktuelle Rheumatologie, (vol. 23), No., pp.109-14.

[10] Caldwell, J. R. and Furst, D. E. (1991): The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis, Semin Arthritis Rheum, (vol. 21), No. 1, pp.1-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1948096

[11] Saag, K. G.; Koehnke, R.; Caldwell, J. R.; Brasington, R.; Burmeister, L. F.; Zimmerman, B.; Kohler, J. A. and Furst, D. E. (1994): Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events, Am J Med, (vol. 96), No. 2, pp.115-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8109596

[12] van Staa, T. P.; Leufkens, H. G.; Abenhaim, L.; Zhang, B. and Cooper, C. (2000): Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, Rheumatology (Oxford), (vol. 39), No. 12, pp.1383-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11136882

[13] Van Staa, T. P.; Leufkens, H. G.; Abenhaim, L.; Zhang, B. and Cooper, C. (2000): Use of oral corticosteroids and risk of fractures, J Bone Miner Res, (vol. 15), No. 6, pp.993-1000. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10841167

[14] de Nijs, R. N.; Jacobs, J. W.; Bijlsma, J. W.; Lems, W. F.; Laan, R. F.; Houben, H. H.; ter Borg, E. J.; Huisman, A. M.; Bruyn, G. A.; van Oijen, P. L.; Westgeest, A. A.; Algra, A. and Hofman, D. M. (2001): Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis, Rheumatology (Oxford), (vol. 40), No. 12, pp.1375-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11752508

[15] Buttgereit, Frank, Wehling M, Burmester GR (1998): A new hypothesis of modular glucocorticoid actions., Arthritis Rheumatism, (vol. 41), No. 5, pp.761-7.

[16] Tyrrell, JB. ( 1995, ): Glucocorticoid therapy, Felig, P, Baxter JD, Frohman LA, Ed, Endocrinology and metabolism (Vol., 3.. ed., p.^pp. 855-82, McGraw-Hill, Inc., New York.

[17] Groner, B, Hynes NE, Rahmsdorf U, Ponta H (1983): Transcription initiation of transfected mouse mammary tumor virus LTR DNA is regulated by glucocorticoid hormones., Nucleic Acids Res, (vol. 11), No. 14, pp.4713-25.

[18] Buttgereit, F. and Scheffold, A. (2002): Rapid glucocorticoid effects on immune cells, Steroids, (vol. 67), No. 6, pp.529-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11960631

[19] Croxtall, J D, Choudhury Q, Flower RJ (2000): Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism, Br J Pharmacol, (vol. 130), No., pp.289-98.

[20] Schmidt, B M, Gerdes D, Feuring M, Falkenstein E, Christ M, Wehling M. (2000): Rapid, nongenomic steroid actions: A new age?, Front Neuroendocrinol, (vol. 21), No. 1, pp.57-94.

[21] Selye, H (1942): Correlation between the chemical structure and the pharmacological actions of the steroids, Endocrinology, (vol. 30), No., pp.437-53.

[22] Edwardson, J A, Bennett GW (1974): Modulation of corticotrophin-releasing factor release from hypothalamic synaptosomes, Nature, (vol. 251), No. 5474, pp.425-7.

[23] Sutter-Dub, M. T. (2002): Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types, Steroids, (vol. 67), No. 2, pp.77-93. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11755172

[24] Boumpas, D T, Chrousos GP, Wilder RL, Cupps TR, Balow JE (1993): Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates, Ann Intern Med, (vol. 119), No. 12, pp.1198-208.

[25] Bamberger, C M, Bamberger AM, de Castro M, Chrousos GP (1995): Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans, J Clin Invest, (vol. 95), No. 6, pp.2435-41.

[26] Adcock, I M (2000): Molecular mechanisms of glucocorticosteroid actions, Pulm Pharmacol Ther, (vol. 13), No. 3, pp.115-26.

[27] Barnes, P J, Karin M (1997): Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases, N Engl J Med, (vol. 336), No. 15, pp.1066-71.

[28] Haddad, E B, Salmon M, Koto H, Barnes PJ, Adcock I, Chung KF (1996): Ozone induction of cytokine-induced neutrophil chemoattractant (CINC) and nuclear factor-kappa b in rat lung: inhibition by corticosteroids, FEBS Lett, (vol. 379), No. 3, pp.265-8.

[29] Boumpas, D T (1996): A novel action of glucocorticoids - NF-kappa B inhibition, Br J Rheumatol, (vol. 35), No. 8, pp.709-10.

[30] Christ, M.; Meyer, C.; Sippel, K. and Wehling, M. (1995): Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha, Biochem Biophys Res Commun, (vol. 213), No. 1, pp.123-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7639725

[31] Wehling, M. (1995): Nongenomic aldosterone effects: the cell membrane as a specific target of mineralocorticoid action, Steroids, (vol. 60), No. 1, pp.153-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7792803

[32] Wehling, M. (1996): Non-genomic steroid action--take a closer look, it's not rare! An invited commentary, Eur J Endocrinol, (vol. 135), No. 3, pp.287-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8890717

[33] Benten, W. P.; Lieberherr, M.; Giese, G.; Wrehlke, C.; Stamm, O.; Sekeris, C. E.; Mossmann, H. and Wunderlich, F. (1999): Functional testosterone receptors in plasma membranes of T cells, Faseb J, (vol. 13), No. 1, pp.123-33. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9872937

[34] Benten, W. P.; Stephan, C. and Wunderlich, F. (2002): B cells express intracellular but not surface receptors for testosterone and estradiol, Steroids, (vol. 67), No. 7, pp.647-54. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11996938

[35] Benten, W. P.; Lieberherr, M.; Sekeris, C. E. and Wunderlich, F. (1997): Testosterone induces Ca2+ influx via non-genomic surface receptors in activated T cells, FEBS Lett, (vol. 407), No. 2, pp.211-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9166901

[36] Benten, W. P.; Stephan, C.; Lieberherr, M. and Wunderlich, F. (2001): Estradiol signaling via sequestrable surface receptors, Endocrinology, (vol. 142), No. 4, pp.1669-77. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11250949

[37] Norfleet, A. M.; Thomas, M. L.; Gametchu, B. and Watson, C. S. (1999): Estrogen receptor-alpha detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked immunocytochemistry, Endocrinology, (vol. 140), No. 8, pp.3805-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10433242

[38] Norfleet, A. M.; Clarke, C. H.; Gametchu, B. and Watson, C. S. (2000): Antibodies to the estrogen receptor-alpha modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors, Faseb J, (vol. 14), No. 1, pp.157-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10627290

[39] Orchinik, M, Murray TF, Moore FL (1991): A corticosteroid receptor in neuronal membranes, Science, (vol. 252), No. 5014, pp.1848-51.

[40] Orchinik, M, Murray TF, Franklin PH, Moore FL (1992): Guanyl nucleotides modulate binding to steroid receptors in neuronal membranes, Proc Natl Acad Sci U S A, (vol. 89), No. 9, pp.3830-4.

[41] Chen, F, Watson CS, Gametchu B (1999): Association of the glucocorticoid receptor alternatively-spliced transcript 1A with the presence of the high molecular weight membrane glucocorticoid receptor in mouse lymphoma cells, J Cell Biochem, (vol. 74), No. 3, pp.430-46.

[42] Chen, F, Watson CS, Gametchu B (1999): Multiple glucocorticoid receptor transcripts in membrane glucocorticoid receptor-enriched S-49 mouse lymphoma cells, J Cell Biochem, (vol. 74), No. 3, pp.418-29.

[43] Gametchu, B, Watson CS, Wu S (1993): Use of receptor antibodies to demonstrate membrane glucocorticoid receptor in cells from human leukemic patients, FASEB J, (vol. 7), No. 13, pp.1283-92.

[44] Gametchu, B, Chen F, Sackey F, Powell C, Watson CS (1999): Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models, Steroids, (vol. 64), No. 1-2, pp.107-19.

[45] Bienert, Maren (2001): Untersuchungen zu Mechanismen nichtgenomischer Glucocorticoidwirkungen: Humboldt-Universität zu Berlin Berlin.

[46] Evans, S J, Murray TF, Moore FL (2000): Partial purification and biochemical characterization of a membrane glucocorticoid receptor from an amphibian brain, J Steroid Biochem Mol Biol, (vol. 72), No. 5, pp.209-21.

[47] Nadal, A.; Ropero, A. B.; Fuentes, E. and Soria, B. (2001): The plasma membrane estrogen receptor: nuclear or unclear?, Trends Pharmacol Sci, (vol. 22), No. 12, pp.597-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11730951

[48] Schmid, D, Burmester GR, Tripmacher R, Kuhnke A, Buttgereit F (2000): Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states, Biosci Rep, (vol. 20), No. 4, pp.289-302.

[49] Buttgereit, F, Brand MD, Muller M (1993): Effects of methylprednisolone on the energy metabolism of quiescent and ConA-stimulated thymocytes of the rat, Biosci Rep, (vol. 13), No. 1, pp.41-52.

[50] Buttgereit, F.; Krauss, S. and Brand, M. D. (1997): Methylprednisolone inhibits uptake of Ca2+ and Na+ ions into concanavalin A-stimulated thymocytes, Biochem J, (vol. 326 ( Pt 2)), No., pp.329-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9291100

[51] Buttgereit, F.; Burmester, G. R. and Brand, M. D. (2000): Bioenergetics of immune functions: fundamental and therapeutic aspects, Immunol Today, (vol. 21), No. 4, pp.192-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10740243

[52] Buttgereit, F.; Brand, M. D. and Burmester, G. R. (1999): Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy, Biochem Pharmacol, (vol. 58), No. 2, pp.363-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10423179

[53] Hafezi-Moghadam, A.; Simoncini, T.; Yang, E.; Limbourg, F. P.; Plumier, J. C.; Rebsamen, M. C.; Hsieh, C. M.; Chui, D. S.; Thomas, K. L.; Prorock, A. J.; Laubach, V. E.; Moskowitz, M. A.; French, B. A.; Ley, K. and Liao, J. K. (2002): Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase, Nat Med, (vol. 8), No. 5, pp.473-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11984591

[54] Reid, I. R. (2000): Glucocorticoid-induced osteoporosis, Baillieres Best Pract Res Clin Endocrinol Metab, (vol. 14), No. 2, pp.279-98. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11035907

[55] Ringe, J. D. (1990): Pathogenese der Kortikoidosteoporose, Fortschr Med, (vol. 108), No. 20, pp.393-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2202618

[56] Magaro, M.; Tricerri, A.; Piane, D.; Zoli, A.; Serra, F.; Altomonte, L. and Mirone, L. (1991): Generalized osteoporosis in non-steroid treated rheumatoid arthritis, Rheumatol Int, (vol. 11), No. 2, pp.73-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1947672

[57] Gough, A. K.; Lilley, J.; Eyre, S.; Holder, R. L. and Emery, P. (1994): Generalised bone loss in patients with early rheumatoid arthritis, Lancet, (vol. 344), No. 8914, pp.23-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7912297

[58] LoCascio, V.; Bonucci, E.; Imbimbo, B.; Ballanti, P.; Adami, S.; Milani, S.; Tartarotti, D. and DellaRocca, C. (1990): Bone loss in response to long-term glucocorticoid therapy, Bone Miner, (vol. 8), No. 1, pp.39-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2306553

[59] Rubin, M. R. and Bilezikian, J. P. (2002): Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence, J Clin Endocrinol Metab, (vol. 87), No. 9, pp.4033-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12213840

[60] Patschan, D.; Loddenkemper, K. and Buttgereit, F. (2001): Molecular mechanisms of glucocorticoid-induced osteoporosis, Bone, (vol. 29), No. 6, pp.498-505. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11728918

[61] Buttgereit, F.; da Silva, J. A.; Boers, M.; Burmester, G. R.; Cutolo, M.; Jacobs, J.; Kirwan, J.; Kohler, L.; Van Riel, P.; Vischer, T. and Bijlsma, J. W. (2002): Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology, Ann Rheum Dis, (vol. 61), No. 8, pp.718-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12117678

[62] Kanis, J. A.; Black, D.; Cooper, C.; Dargent, P.; Dawson-Hughes, B.; De Laet, C.; Delmas, P.; Eisman, J.; Johnell, O.; Jonsson, B.; Melton, L.; Oden, A.; Papapoulos, S.; Pols, H.; Rizzoli, R.; Silman, A. and Tenenhouse, A. (2002): A new approach to the development of assessment guidelines for osteoporosis, Osteoporos Int, (vol. 13), No. 7, pp.527-36. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12111012

[63] Kanis, J. A. (1997): Diagnosis of osteoporosis, Osteoporos Int, (vol. 7 Suppl 3), No., pp.S108-16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9536315

[64] Marshall, D.; Johnell, O. and Wedel, H. (1996): Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, Bmj, (vol. 312), No. 7041, pp.1254-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8634613

[65] (1993): Consensus Development Conference on Osteoporosis. Hong Kong, April 1-2, 1993, Am J Med, (vol. 95), No. 5A, pp.1S-78S. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8256786

[66] (1994): Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group, World Health Organ Tech Rep Ser, (vol. 843), No., pp.1-129. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7941614

[67] Kanis, J. A.; Johnell, O.; Oden, A.; Sembo, I.; Redlund-Johnell, I.; Dawson, A.; De Laet, C. and Jonsson, B. (2000): Long-term risk of osteoporotic fracture in Malmo, Osteoporos Int, (vol. 11), No. 8, pp.669-74. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11095169

[68] Kanis, J. A. and Gluer, C. C. (2000): An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation, Osteoporos Int, (vol. 11), No. 3, pp.192-202. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10824234

[69] Johnell, O.; Oden, A.; De Laet, C.; Garnero, P.; Delmas, P. D. and Kanis, J. A. (2002): Biochemical indices of bone turnover and the assessment of fracture probability, Osteoporos Int, (vol. 13), No. 7, pp.523-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12111011

[70] Seibel, M J: Biochemische Marker des Knochenstoffwechsels und ihre Anwendung in der Osteoporose-Diagnostik, Dambacher, M A; Ringe, J D and Schacht, E, Eds, Programmed - Moderne Osteoporosetherapie Jhrg. 20 Suppl. 1 (Vol., p.^pp. 19-24, Programmed Verlag, Frankfurt.

[71] Miller, P. D.; Baran, D. T.; Bilezikian, J. P.; Greenspan, S. L.; Lindsay, R.; Riggs, B. L. and Watts, N. B. (1999): Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel, J Clin Densitom, (vol. 2), No. 3, pp.323-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10548827

[72] Kanis, J. A.; Johnell, O.; Oden, A.; Dawson, A.; De Laet, C. and Jonsson, B. (2001): Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds, Osteoporos Int, (vol. 12), No. 12, pp.989-95. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11846333

[73] Garnero, P. and Delmas, P. D. (1998): Biochemical markers of bone turnover. Applications for osteoporosis, Endocrinol Metab Clin North Am, (vol. 27), No. 2, pp.303-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9669140

[74] Bauer, D. C.; Sklarin, P. M.; Stone, K. L.; Black, D. M.; Nevitt, M. C.; Ensrud, K. E.; Arnaud, C. D.; Genant, H. K.; Garnero, P.; Delmas, P. D.; Lawaetz, H. and Cummings, S. R. (1999): Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures, J Bone Miner Res, (vol. 14), No. 8, pp.1404-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10457273

[75] Ross, P. D. and Knowlton, W. (1998): Rapid bone loss is associated with increased levels of biochemical markers, J Bone Miner Res, (vol. 13), No. 2, pp.297-302. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9495524

[76] Looker, A. C.; Bauer, D. C.; Chesnut, C. H., 3rd; Gundberg, C. M.; Hochberg, M. C.; Klee, G.; Kleerekoper, M.; Watts, N. B. and Bell, N. H. (2000): Clinical use of biochemical markers of bone remodeling: current status and future directions, Osteoporos Int, (vol. 11), No. 6, pp.467-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10982161

[77] Garnero, P.; Hausherr, E.; Chapuy, M. C.; Marcelli, C.; Grandjean, H.; Muller, C.; Cormier, C.; Breart, G.; Meunier, P. J. and Delmas, P. D. (1996): Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study, J Bone Miner Res, (vol. 11), No. 10, pp.1531-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8889854

[78] Melton, L. J., 3rd; Khosla, S.; Atkinson, E. J.; O'Fallon, W. M. and Riggs, B. L. (1997): Relationship of bone turnover to bone density and fractures, J Bone Miner Res, (vol. 12), No. 7, pp.1083-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9200008

[79] Riggs, B. L. (2000): Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients?, Bone, (vol. 26), No. 6, pp.551-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10831924

[80] Riggs, B. L.; Melton, L. J., 3rd and O'Fallon, W. M. (1996): Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy, Bone, (vol. 18), No. 3 Suppl, pp.197S-201S. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8777088

[81] Berki, T.; Kumanovics, G.; Kumanovics, A.; Falus, A.; Ujhelyi, E. and Nemeth, P. (1998): Production and flow cytometric application of a monoclonal anti-glucocorticoid receptor antibody, J Immunol Methods, (vol. 214), No. 1-2, pp.19-27. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9692855

[82] Scheffold, A. and Radbruch, A. ( 1998, ): Phenotyping and separation of leucocyte populations based on affinity labelling, Methods in Microbiology (Vol. 25), p.^pp. 23-56, Academic-Press-Ltd.

[83] Scheffold, A.; Assenmacher, M.; Reiners-Schramm, L.; Lauster, R. and Radbruch, A. (2000): High-sensitivity immunofluorescence for detection of the pro- and anti-inflammatory cytokines gamma interferon and interleukin-10 on the surface of cytokine-secreting cells, Nat Med, (vol. 6), No. 1, pp.107-10. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10613835

[84] Shapiro, H ( 1988, ), in: Practical Flow Cytometry (Vol., p.^pp., Alan R. Liss, New York.

[85] Scheffold, A.; Miltenyi, S. and Radbruch, A. (1995): Magnetofluorescent liposomes for increased sensitivity of immunofluorescence, Immunotechnology, (vol. 1), No. 2, pp.127-37. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9373341

[86] Salaffi, F.; Peroni, M. and Ferraccioli, G. F. (2000): Discriminating ability of composite indices for measuring disease activity in rheumatoid arthritis: a comparison of the Chronic Arthritis Systemic Index, Disease Activity Score and Thompson's articular index, Rheumatology (Oxford), (vol. 39), No. 1, pp.90-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10662880

[87] Bullinger, Monika and Kirchberger, Inge (1998): SF-36 Fragebogen zum Gesundheitszustand - Handanweisungen (vol., Hogrefe-Verlag, Göttingen, Bern, Toronto, Seattle.

[88] Harris, E. D., Jr.; Emkey, R. D.; Nichols, J. E. and Newberg, A. (1983): Low dose prednisone therapy in rheumatoid arthritis: a double blind study, J Rheumatol, (vol. 10), No. 5, pp.713-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6358491

[89] Verhoeven, A. C.; Boers, M.; te Koppele, J. M.; van der Laan, W. H.; Markusse, H. M.; Geusens, P. and van der Linden, S. (2001): Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone, Rheumatology (Oxford), (vol. 40), No. 11, pp.1231-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11709606

[90] Espallargues, M.; Sampietro-Colom, L.; Estrada, M. D.; Sola, M.; del Rio, L.; Setoain, J. and Granados, A. (2001): Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature, Osteoporos Int, (vol. 12), No. 10, pp.811-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11716183

[91] Reid, I. R. (2001): Time to end steroid-induced fractures, Arch Dermatol, (vol. 137), No. 4, pp.493-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11295932

[92] van Staa, T. P.; Abenhaim, L.; Cooper, C.; Zhang, B. and Leufkens, H. G. (2001): Public health impact of adverse bone effects of oral corticosteroids, Br J Clin Pharmacol, (vol. 51), No. 6, pp.601-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11422020

[93] Melton, L. J., 3rd (1995): How many women have osteoporosis now?, J Bone Miner Res, (vol. 10), No. 2, pp.175-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7754796

[94] Tripathi, R. C.; Parapuram, S. K.; Tripathi, B. J.; Zhong, Y. and Chalam, K. V. (1999): Corticosteroids and glaucoma risk, Drugs Aging, (vol. 15), No. 6, pp.439-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10641955

[95] Bijlsma, J. W.; Van Everdingen, A. A.; Huisman, M.; De Nijs, R. N. and Jacobs, J. W. (2002): Glucocorticoids in rheumatoid arthritis: effects on erosions and bone, Ann N Y Acad Sci, (vol. 966), No., pp.82-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12114262

[96] Cohen, M. D. and Conn, D. L. (1997): Benefits of low-dose corticosteroids in rheumatoid arthritis, Bull Rheum Dis, (vol. 46), No. 4, pp.4-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9188203

[97] Kirwan, J. R. (2001): Systemic low-dose glucocorticoid treatment in rheumatoid arthritis, Rheum Dis Clin North Am, (vol. 27), No. 2, pp.389-403, ix-x. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11396099

[98] van Everdingen, A. A.; Jacobs, J. W.; Siewertsz Van Reesema, D. R. and Bijlsma, J. W. (2002): Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial, Ann Intern Med, (vol. 136), No. 1, pp.1-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11777359

[99] (1946): Preamble to the Constitution of the World Health Organization, International Health Conference.

[100] Stavem, K.; Lossius, M. I.; Kvien, T. K. and Guldvog, B. (2000): The health-related quality of life of patients with epilepsy compared with angina pectoris, rheumatoid arthritis, asthma and chronic obstructive pulmonary disease, Qual Life Res, (vol. 9), No. 7, pp.865-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11297029

[101] Evans, S. J.; Moore, F. L. and Murray, T. F. (1998): Solubilization and pharmacological characterization of a glucocorticoid membrane receptor from an amphibian brain, J Steroid Biochem Mol Biol, (vol. 67), No. 1, pp.1-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9780023

[102] Grote, H.; Ioannou, I.; Voigt, J. and Sekeris, C. E. (1993): Localization of the glucocorticoid receptor in rat liver cells: evidence for plasma membrane bound receptor, Int J Biochem, (vol. 25), No. 11, pp.1593-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8288028

[103] Christ, M.; Eisen, C.; Aktas, J.; Theisen, K. and Wehling, M. (1993): The inositol-1,4,5-trisphosphate system is involved in rapid effects of aldosterone in human mononuclear leukocytes, J Clin Endocrinol Metab, (vol. 77), No. 6, pp.1452-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8263127

[104] Wehling, M.; Neylon, C. B.; Fullerton, M.; Bobik, A. and Funder, J. W. (1995): Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells, Circ Res, (vol. 76), No. 6, pp.973-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7758168

[105] Christ, M.; Gunther, A.; Heck, M.; Schmidt, B. M.; Falkenstein, E. and Wehling, M. (1999): Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells, Circulation, (vol. 99), No. 11, pp.1485-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10086974

[106] Borski, R. J. (2000): Nongenomic membrane actions of glucocorticoids in vertebrates, Trends Endocrinol Metab, (vol. 11), No. 10, pp.427-36. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11091121

[107] Borski, R. J.; Hyde, G. N. and Fruchtman, S. (2002): Signal transduction mechanisms mediating rapid, nongenomic effects of cortisol on prolactin release, Steroids, (vol. 67), No. 6, pp.539-48. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11960633

[108] Solito, E.; Mulla, A.; Morris, J. F.; Christian, H. C.; Flower, R. J. and Buckingham, J. C. (2003): Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase, Endocrinology, (vol. 144), No. 4, pp.1164-74. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12639897

[109] Cato, A. C.; Nestl, A. and Mink, S. (2002): Rapid actions of steroid receptors in cellular signaling pathways, Sci STKE, (vol. 2002), No. 138, p.RE9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12084906

[110] Razandi, M.; Pedram, A.; Greene, G. L. and Levin, E. R. (1999): Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells, Mol Endocrinol, (vol. 13), No. 2, pp.307-19. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9973260

[111] Tanaka, H.; Akama, H.; Ichikawa, Y.; Homma, M. and Oshima, H. (1991): Glucocorticoid receptors in normal leukocytes: effects of age, gender, season, and plasma cortisol concentrations, Clin Chem, (vol. 37), No. 10 Pt 1, pp.1715-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1914170

[112] Gametchu, B. (1987): Glucocorticoid receptor-like antigen in lymphoma cell membranes: correlation to cell lysis, Science, (vol. 236), No. 4800, pp.456-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3563523

[113] Andreae, J.; Tripmacher, R.; Weltrich, R.; Rohde, W.; Keitzer, R.; Wahn, U.; Paul, K. and Buttgereit, F. (2001): Effect of glucocorticoid therapy on glucocorticoid receptors in children with autoimmune diseases, Pediatr Res, (vol. 49), No. 1, pp.130-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11134503

[114] Zola, H.; Flego, L. and Sheldon, A. (1992): Detection of cytokine receptors by high-sensitivity immunofluorescence/flow cytometry, Immunobiology, (vol. 185), No. 2-4, pp.350-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1452210

[115] Bruno, L.; Scheffold, A.; Radbruch, A. and Owen, M. J. (1999): Threshold of pre-T-cell-receptor surface expression is associated with alphabeta T-cell lineage commitment, Curr Biol, (vol. 9), No. 11, pp.559-68. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10359697

[116] Arnett, F. C.; Edworthy, S. M.; Bloch, D. A.; McShane, D. J.; Fries, J. F.; Cooper, N. S.; Healey, L. A.; Kaplan, S. R.; Liang, M. H.; Luthra, H. S. and et al. (1988): The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, (vol. 31), No. 3, pp.315-24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3358796

[117] Russell, K. S.; Haynes, M. P.; Sinha, D.; Clerisme, E. and Bender, J. R. (2000): Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling, Proc Natl Acad Sci U S A, (vol. 97), No. 11, pp.5930-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10823945

[118] Dowd, D. R.; Ryerse, J. S.; MacDonald, P. N.; Miesfeld, R. L. and Kamradt, M. C. (1997): Crosstalk during Ca2+-, cAMP-, and glucocorticoid-induced gene expression in lymphocytes, Mol Cell Endocrinol, (vol. 128), No. 1-2, pp.29-37. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9140073

[119] Asada, A.; Zhao, Y.; Kondo, S. and Iwata, M. (1998): Induction of thymocyte apoptosis by Ca2+-independent protein kinase C (nPKC) activation and its regulation by calcineurin activation, J Biol Chem, (vol. 273), No. 43, pp.28392-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9774466

[120] Kofler, R. (2000): The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells, Histochem Cell Biol, (vol. 114), No. 1, pp.1-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10959816

[121] Thompson, E. B. (1999): Mechanisms of T-cell Apoptosis Induced by Glucocorticoids, Trends Endocrinol Metab, (vol. 10), No. 9, pp.353-358. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10511694

[122] Gold, R.; Buttgereit, F. and Toyka, K. V. (2001): Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders, J Neuroimmunol, (vol. 117), No. 1-2, pp.1-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11430999

[123] Kousteni, S.; Bellido, T.; Plotkin, L. I.; O'Brien, C. A.; Bodenner, D. L.; Han, L.; Han, K.; DiGregorio, G. B.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S.; Roberson, P. K.; Weinstein, R. S.; Jilka, R. L. and Manolagas, S. C. (2001): Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity, Cell, (vol. 104), No. 5, pp.719-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11257226

[124] Lipworth, B. J. (2000): Therapeutic implications of non-genomic glucocorticoid activity, Lancet, (vol. 356), No. 9224, pp.87-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10963239

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: